130 related articles for article (PubMed ID: 11509591)
1. Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance.
den Boer AT; Diehl L; van Mierlo GJ; van der Voort EI; Fransen MF; Krimpenfort P; Melief CJ; Offringa R; Toes RE
J Immunol; 2001 Sep; 167(5):2522-8. PubMed ID: 11509591
[TBL] [Abstract][Full Text] [Related]
2. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
[TBL] [Abstract][Full Text] [Related]
3. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.
Toes RE; Offringa R; Blom RJ; Melief CJ; Kast WM
Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7855-60. PubMed ID: 8755566
[TBL] [Abstract][Full Text] [Related]
4. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.
Diehl L; den Boer AT; Schoenberger SP; van der Voort EI; Schumacher TN; Melief CJ; Offringa R; Toes RE
Nat Med; 1999 Jul; 5(7):774-9. PubMed ID: 10395322
[TBL] [Abstract][Full Text] [Related]
5. Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC.
Schoenberger SP; Jonges LE; Mooijaart RJ; Hartgers F; Toes RE; Kast WM; Melief CJ; Offringa R
Cancer Res; 1998 Jul; 58(14):3094-100. PubMed ID: 9679976
[TBL] [Abstract][Full Text] [Related]
6. The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment.
den Boer AT; van Mierlo GJ; Fransen MF; Melief CJ; Offringa R; Toes RE
J Immunol; 2004 May; 172(10):6074-9. PubMed ID: 15128791
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic differences between a T cell-tolerizing and a T cell-activating peptide.
Weijzen S; Meredith SC; Velders MP; Elmishad AG; Schreiber H; Kast WM
J Immunol; 2001 Jun; 166(12):7151-7. PubMed ID: 11390461
[TBL] [Abstract][Full Text] [Related]
8. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.
Toes RE; Blom RJ; Offringa R; Kast WM; Melief CJ
J Immunol; 1996 May; 156(10):3911-8. PubMed ID: 8621930
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells.
Toes RE; van der Voort EI; Schoenberger SP; Drijfhout JW; van Bloois L; Storm G; Kast WM; Offringa R; Melief CJ
J Immunol; 1998 May; 160(9):4449-56. PubMed ID: 9574550
[TBL] [Abstract][Full Text] [Related]
10. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.
Ito D; Ogasawara K; Iwabuchi K; Inuyama Y; Onoé K
J Immunol; 2000 Feb; 164(3):1230-5. PubMed ID: 10640735
[TBL] [Abstract][Full Text] [Related]
11. Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction.
Boonman ZF; van Mierlo GJ; Fransen MF; Franken KL; Offringa R; Melief CJ; Jager MJ; Toes RE
J Immunol; 2004 Feb; 172(3):1567-74. PubMed ID: 14734736
[TBL] [Abstract][Full Text] [Related]
12. CD4+ T cells can protect APC from CTL-mediated elimination.
Mueller SN; Jones CM; Stock AT; Suter M; Heath WR; Carbone FR
J Immunol; 2006 Jun; 176(12):7379-84. PubMed ID: 16751382
[TBL] [Abstract][Full Text] [Related]
13. The cross-priming APC requires a Rel-dependent signal to induce CTL.
Mintern JD; Belz G; Gerondakis S; Carbone FR; Heath WR
J Immunol; 2002 Apr; 168(7):3283-7. PubMed ID: 11907083
[TBL] [Abstract][Full Text] [Related]
14. Lipopolysaccharide modulation of dendritic cells is insufficient to mature dendritic cells to generate CTLs from naive polyclonal CD8+ T cells in vitro, whereas CD40 ligation is essential.
Kelleher M; Beverley PC
J Immunol; 2001 Dec; 167(11):6247-55. PubMed ID: 11714787
[TBL] [Abstract][Full Text] [Related]
15. The role of CD40 in peripheral T cell tolerance and immunity.
Diehl L; Den Boer AT; van der Voort EI; Melief CJ; Offringa R; Toes RE
J Mol Med (Berl); 2000; 78(7):363-71. PubMed ID: 11043379
[TBL] [Abstract][Full Text] [Related]
16. CD40 ligation in the presence of self-reactive CD8 T cells leads to severe immunopathology.
Roth E; Schwartzkopff J; Pircher H
J Immunol; 2002 May; 168(10):5124-9. PubMed ID: 11994466
[TBL] [Abstract][Full Text] [Related]
17. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles.
Storni T; Lechner F; Erdmann I; Bächi T; Jegerlehner A; Dumrese T; Kündig TM; Ruedl C; Bachmann MF
J Immunol; 2002 Mar; 168(6):2880-6. PubMed ID: 11884458
[TBL] [Abstract][Full Text] [Related]
18. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
[TBL] [Abstract][Full Text] [Related]
19. Cutting edge: a crucial role for B7-CD28 in transmitting T help from APC to CTL.
Prilliman KR; Lemmens EE; Palioungas G; Wolfe TG; Allison JP; Sharpe AH; Schoenberger SP
J Immunol; 2002 Oct; 169(8):4094-7. PubMed ID: 12370335
[TBL] [Abstract][Full Text] [Related]
20. In vivo cross-presentation of a soluble protein antigen: kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes.
Nelson D; Bundell C; Robinson B
J Immunol; 2000 Dec; 165(11):6123-32. PubMed ID: 11086045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
